002424.SZ
Guizhou Bailing Group Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 4.55
+0.66%Sep 9, 2026, 09:18 UTC
China Securities Regulatory Commission issued an advance notice of administrative penalty to Jiang Wei, actual controller of ST Bailing, for alleged insider trading and disclosure violations.
Sep 9, 2026, 09:18 UTC
ST Bailing completed the cancellation of 12.0969 million repurchased shares, reducing its total share capital by 0.87%, effective September 8, 2026.
Source:Aug 31, 2026, 09:11 UTC
ST Bailing's wholly-owned subsidiary BaiLing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration to conduct clinical trials for the inhaled drug BD77 for chronic obstructive pulmonary disease.
Aug 28, 2026, 08:41 UTC
ST Bailing's wholly-owned subsidiary received pre-approval from the Macao SAR Drug Administration (ISAF) to conduct a Phase III clinical trial for its traditional Chinese medicine product Tangningtongluo Tablet, the first such pre-approval for a new TCM drug in Macao.
Source: